[
    [
        {
            "time": "",
            "original_text": "天坛生物：目前公司所属血液制品企业拥有单采血浆站（含分站）74家(包括已获批未建)",
            "features": {
                "keywords": [
                    "天坛生物",
                    "血液制品",
                    "单采血浆站",
                    "74家"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：目前公司所属血液制品企业拥有单采血浆站（含分站）74家(包括已获批未建)",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：持续开展COVID-19人免疫球蛋白有效性的相关研究",
            "features": {
                "keywords": [
                    "天坛生物",
                    "COVID-19",
                    "免疫球蛋白",
                    "有效性",
                    "研究"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物：持续开展COVID-19人免疫球蛋白有效性的相关研究",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：医保谈判落地 释放积极信号",
            "features": {
                "keywords": [
                    "医药生物",
                    "医保谈判",
                    "积极信号"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：医保谈判落地 释放积极信号",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]